Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment.
Russell AS, Wallenstein GV, Li T, Martin MC, Maclean R, Blaisdell B, Gajria K, Cole JC, Becker JC, Emery P. Russell AS, et al. Among authors: wallenstein gv. Ann Rheum Dis. 2007 Feb;66(2):189-94. doi: 10.1136/ard.2006.057018. Epub 2006 Sep 19. Ann Rheum Dis. 2007. PMID: 16984942 Free PMC article. Clinical Trial.
Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial.
Westhovens R, Cole JC, Li T, Martin M, Maclean R, Lin P, Blaisdell B, Wallenstein GV, Aranda R, Sherrer Y. Westhovens R, et al. Among authors: wallenstein gv. Rheumatology (Oxford). 2006 Oct;45(10):1238-46. doi: 10.1093/rheumatology/kel066. Epub 2006 Mar 27. Rheumatology (Oxford). 2006. PMID: 16567357 Clinical Trial.
Treatment impact on estimated medical expenditure and job loss likelihood in rheumatoid arthritis: re-examining quality of life outcomes from a randomized placebo-controlled clinical trial with abatacept.
Cole JC, Li T, Lin P, MacLean R, Wallenstein GV. Cole JC, et al. Among authors: wallenstein gv. Rheumatology (Oxford). 2008 Jul;47(7):1044-50. doi: 10.1093/rheumatology/ken141. Epub 2008 May 17. Rheumatology (Oxford). 2008. PMID: 18487628 Clinical Trial.
A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone.
Kremer JM, Cohen S, Wilkinson BE, Connell CA, French JL, Gomez-Reino J, Gruben D, Kanik KS, Krishnaswami S, Pascual-Ramos V, Wallenstein G, Zwillich SH. Kremer JM, et al. Arthritis Rheum. 2012 Apr;64(4):970-81. doi: 10.1002/art.33419. Epub 2011 Oct 17. Arthritis Rheum. 2012. PMID: 22006202 Free article. Clinical Trial.
Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.
Kremer J, Li ZG, Hall S, Fleischmann R, Genovese M, Martin-Mola E, Isaacs JD, Gruben D, Wallenstein G, Krishnaswami S, Zwillich SH, Koncz T, Riese R, Bradley J. Kremer J, et al. Ann Intern Med. 2013 Aug 20;159(4):253-61. doi: 10.7326/0003-4819-159-4-201308200-00006. Ann Intern Med. 2013. PMID: 24026258 Clinical Trial.
63 results